Does Blue Cross Blue Shield of Illinois Cover Eliquis?

What Is Eliquis and Why Do Patients Need It?

Eliquis (apixaban) is a direct oral anticoagulant (DOAC) that selectively inhibits factor Xa, the enzyme at the convergence point of the intrinsic and extrinsic coagulation cascades. The FDA approved apixaban in 2012 for reducing stroke risk in non-valvular atrial fibrillation, and subsequent approvals covered DVT and PE treatment and prophylaxis after hip or knee replacement surgery. [1]

Clinical Evidence Driving Prescriptions

The ARISTOTLE trial (N=18,201) compared apixaban 5 mg twice daily against warfarin in patients with atrial fibrillation. Apixaban reduced the rate of stroke or systemic embolism by 21% (1.27% vs. 1.60% per year, P<0.001), cut major bleeding by 31%, and reduced all-cause mortality by 11% compared with warfarin. [2] That mortality benefit is one reason cardiologists and hematologists prefer it over older vitamin K antagonists.

The AMPLIFY trial (N=5,395) established apixaban's role in acute DVT and PE. Patients on apixaban had a 69% relative reduction in major bleeding compared with conventional enoxaparin-warfarin therapy (0.6% vs. 1.8%, P<0.001), with comparable efficacy in preventing recurrent VTE. [3]

FDA-Approved Indications

The FDA label covers four primary indications: [1]

• Non-valvular atrial fibrillation: stroke and systemic embolism prevention
• DVT treatment
• PE treatment
• VTE prophylaxis after elective hip or knee replacement surgery

BCBSIL coverage decisions follow the FDA label closely. Off-label requests, such as antiphospholipid syndrome with triple positivity, are almost always denied without strong supporting documentation.

How BCBSIL Formularies Classify Eliquis

BCBSIL operates multiple formulary tiers across its commercial PPO, HMO, BlueChoice, and Medicare Advantage product lines. Eliquis sits at Tier 3 (preferred brand) or Tier 4 (non-preferred brand) on most of these plans. The exact tier depends on the employer group contract or individual plan year, so the member's Summary of Benefits and Coverage (SBC) is the authoritative source.

Tier Placement and Cost-Sharing

On a typical BCBSIL commercial PPO in 2025:

• Tier 3 preferred brand: $47 to $85 copay per 30-day supply after deductible
• Tier 4 non-preferred brand: $100 to $150+ per 30-day supply after deductible
• High-deductible health plans (HDHPs): full negotiated price applies until the deductible is met, which can run $300 to $500 per 30-day fill

On BCBSIL Medicare Advantage Part D plans, Eliquis commonly lands in Tier 3 with a cost-sharing of approximately $47 per fill during the initial coverage phase, though this climbs in the coverage gap (the "donut hole") unless the patient qualifies for Extra Help. [4]

Prior Authorization Criteria

Most BCBSIL commercial and Medicare Advantage plans require prior authorization (PA) for Eliquis. Standard PA criteria typically include:

1. A confirmed diagnosis matching an FDA-approved indication (ICD-10 codes I48.x for AFib, I82.x for DVT, I26.x for PE)
2. Documentation that the prescriber has evaluated renal function (CrCl calculation per the Cockcroft-Gault equation)
3. Confirmation that the patient does not have mechanical heart valves or moderate-to-severe mitral stenosis (conditions where DOACs are contraindicated per ACC/AHA guidelines) [5]
4. For some plans: evidence of trial or contraindication to warfarin or rivaroxaban (step therapy)

Step therapy requirements are common on employer-sponsored BCBSIL plans. Illinois law (215 ILCS 5/356z.51) allows prescribers to request a step therapy override when a clinically appropriate alternative was already tried and failed, caused an adverse reaction, or is contraindicated. A prescriber attestation letter citing the specific clinical reason is usually sufficient.

Quantity Limits

BCBSIL formularies generally allow a 30-day supply at retail and a 90-day supply at preferred mail-order pharmacies. Eliquis 2.5 mg and 5 mg tablets each have quantity limits aligned with FDA-labeled dosing. Requests for doses outside the label (e.g., higher doses for mechanical valves) are routinely denied. [1]

How to Get Eliquis Covered: A Step-by-Step Process

Getting Eliquis approved through BCBSIL involves several steps that move in a predictable sequence. Knowing each stage in advance saves time and reduces gaps in anticoagulation therapy.

Step 1: Confirm Your Plan's Formulary

Log into bcbsil.com and search the drug formulary tool using the member ID from your insurance card. Confirm the tier, whether PA is required, and whether step therapy applies to your specific plan year. Formularies reset on January 1 each year, so coverage terms from 2024 may not apply in 2025.

Step 2: Submit a Prior Authorization Request

The prescriber's office submits PA through BCBSIL's online portal, by fax, or via a clearinghouse like CoverMyMeds. The PA request must include:

• The patient's diagnosis with supporting ICD-10 code
• Relevant lab values (CrCl, CBC if bleeding risk is a question)
• Clinical notes confirming the indication
• For AFib: CHA2DS2-VASc score (2018 ACC/AHA/HRS guidelines recommend anticoagulation for scores of 2 or more in men and 3 or more in women) [5]

BCBSIL must respond to urgent PA requests within 72 hours and non-urgent requests within 15 business days under Illinois Department of Insurance regulations.

Step 3: Respond to a Step Therapy Requirement

If the PA is conditionally approved pending a step therapy trial, the prescriber has two options. They can document that warfarin is contraindicated (labile INR, drug interactions, patient non-adherence history, or preference after informed discussion), or they can invoke Illinois's step therapy override statute. Citing the ARISTOTLE trial's mortality data and the patient's specific bleeding risk factors often satisfies BCBSIL's medical review team. [2]

Step 4: Appeal a Denial

If the PA is denied, the prescriber and patient can file a Level 1 internal appeal. The written appeal must be submitted within 180 days of the denial notice on most commercial BCBSIL plans. The appeal packet should include:

• The denial letter with the specific reason code
• A letter of medical necessity from the cardiologist or hematologist
• Relevant peer-reviewed evidence (ARISTOTLE, AMPLIFY trial data work well here) [2][3]
• Any contraindication documentation for covered alternatives

If the Level 1 appeal is denied, an external independent review is available under Illinois law. The Illinois Department of Insurance oversees this process and the external reviewer's decision is binding on BCBSIL for most plan types.

Reducing Out-of-Pocket Cost for Eliquis

Even with coverage, Tier 3 and Tier 4 cost-sharing can burden patients on fixed incomes or HDHPs. Several programs can cut the actual out-of-pocket cost to near zero.

Bristol-Myers Squibb / Pfizer Patient Assistance

The Eliquis manufacturer copay card (available at bms.com and pfizer.com) reduces cost-sharing to $10 per month for commercially insured patients who are not enrolled in a federal or state government program (Medicare, Medicaid, CHIP, TRICARE). [6] Patients must meet income and insurance eligibility requirements. The card covers up to $6,400 in savings per calendar year.

Bristol-Myers Squibb Patient Assistance Program

For uninsured or underinsured patients who meet income criteria, the BMS Patient Assistance Foundation provides Eliquis at no cost. The income threshold is generally at or below 400% of the federal poverty level, though exceptions exist. Applications are processed through the prescriber's office. [6]

NeedyMeds and RxAssist

Non-profit databases like NeedyMeds (needymeds.org) catalog state-level pharmaceutical assistance programs in Illinois. These are particularly relevant for patients in the Medicare coverage gap who cannot use the commercial copay card.

90-Day Mail Order

Using a BCBSIL-preferred mail-order pharmacy typically reduces the per-unit cost by 10 to 20% compared with retail, because mail-order dispensing fees are lower. Patients on stable anticoagulation therapy are good candidates for this option.

Eliquis vs. Covered Alternatives on BCBSIL Formularies

Understanding how BCBSIL prices competing anticoagulants helps patients and prescribers make informed decisions if cost is a barrier.

Warfarin (Generic)

Generic warfarin is a Tier 1 generic on virtually every BCBSIL formulary, with copays of $0 to $10 per 30-day supply. The tradeoff is intensive monitoring (target INR 2.0 to 3.0), multiple drug and food interactions, and a narrower therapeutic index. The ARISTOTLE trial's 31% reduction in major bleeding with apixaban versus warfarin quantifies the clinical cost of choosing the cheaper option for many patients. [2]

Rivaroxaban (Xarelto)

Rivaroxaban (Xarelto) is another factor Xa inhibitor with a similar BCBSIL formulary tier to Eliquis. Some plans place rivaroxaban at Tier 3 preferred over Eliquis, making step therapy to rivaroxaban a common PA requirement. The ROCKET-AF trial (N=14,264) found rivaroxaban non-inferior to warfarin for AFib stroke prevention but showed no statistically significant all-cause mortality benefit. [7] That distinction matters when constructing a medical necessity appeal for Eliquis.

Dabigatran (Pradaxa)

Dabigatran is a direct thrombin inhibitor approved for AFib and VTE. The RE-LY trial (N=18,113) showed dabigatran 150 mg twice daily reduced stroke by 35% versus warfarin but with higher GI bleeding rates. [8] Patients with GI intolerance or renal impairment (CrCl <30 mL/min) are typically not candidates. BCBSIL tier placement is similar to Eliquis across most plans.

Edoxaban (Savaysa)

Edoxaban is less commonly prescribed and may sit at Tier 4 on some BCBSIL plans. The ENGAGE AF-TIMI 48 trial (N=21,105) showed edoxaban 60 mg once daily was non-inferior to warfarin for AFib stroke prevention with significantly less bleeding. [9] Its once-daily dosing is an advantage, but bioavailability falls with CrCl above 95 mL/min, limiting its use in some younger, high-renal-function patients.

The HealthRX BCBSIL DOAC Selection Framework below summarizes how clinical factors interact with formulary placement to guide the most cost-effective choice for each patient profile.

| Patient Profile | Preferred DOAC | BCBSIL Cost Signal | Key Trial | |---|---|---|---| | AFib, normal renal function, bleeding-risk concern | Apixaban (Eliquis) | Tier 3/4, PA likely | ARISTOTLE [2] | | AFib, prior GI bleed | Apixaban (Eliquis) | Tier 3/4, PA likely | ARISTOTLE [2] | | AFib, step therapy required first | Rivaroxaban (Xarelto) | Tier 3 often preferred | ROCKET-AF [7] | | DVT/PE, acute treatment | Apixaban (Eliquis) | Tier 3/4, PA likely | AMPLIFY [3] | | AFib, renal CrCl <30 mL/min | Warfarin | Tier 1, no PA | N/A | | Budget-limited, no contraindication to monitoring | Warfarin | Tier 1, no PA | N/A |

What Illinois Law Says About Insurance Coverage of Anticoagulants

Illinois has several statutes that directly affect how BCBSIL must handle Eliquis claims.

Step Therapy Override (215 ILCS 5/356z.51)

Illinois enacted a step therapy override law requiring insurers to grant an exception when: the required first-step drug was previously tried and was ineffective, caused an adverse event, is contraindicated, or would delay needed care. Prescribers submit an override request with clinical documentation, and BCBSIL must respond within 72 hours for urgent cases.

External Review Rights

Under the Illinois Insurance Code (215 ILCS 5/155.22b), any enrollee whose internal appeal is denied can request an independent external review. The external reviewer must be an independent review organization certified by the Illinois Department of Insurance. Their decision binds BCBSIL. This pathway is particularly useful when the denial is based on a step therapy requirement that the prescriber believes is clinically inappropriate.

ACA Formulary Protections

The Affordable Care Act prohibits placing all drugs in a therapeutic class on a specialty tier to discriminate against high-cost conditions. While Eliquis is not technically a specialty drug, complaints filed with the Illinois Department of Insurance have successfully challenged formulary designs that effectively make a medically necessary drug inaccessible. [10]

Medicare Part D and BCBSIL Medicare Advantage Specifics

BCBSIL's Medicare Advantage plans (branded under various product names) include Part D drug coverage. Medicare's coverage rules for Eliquis differ from commercial rules in a few ways.

CMS Protected Class Provisions

CMS designates certain drug categories as "protected classes," requiring Part D plans to cover all or substantially all drugs in those classes. Anticoagulants are not currently a CMS-protected class, which means BCBSIL Medicare Advantage plans can apply PA and step therapy. [4]

Low-Income Subsidy (Extra Help)

Medicare beneficiaries who qualify for Extra Help (also called the Low-Income Subsidy) pay no more than $11.20 per fill for covered drugs in 2025, including Eliquis if it is on the plan formulary. Income and asset limits apply; applications are filed through the Social Security Administration.

Annual Notice of Change

BCBSIL must send Medicare Advantage members an Annual Notice of Change (ANOC) by September 30 each year detailing formulary changes effective January 1. Patients who see Eliquis moved to a higher tier or removed from the formulary have a special enrollment period to switch plans during the October 15 to December 7 Medicare Annual Enrollment Period.

When Eliquis Is Not Covered: Clinical Scenarios That Trigger Denials

Knowing the most common denial reasons helps prescribers submit stronger initial PA requests.

Mechanical Heart Valves

The RE-ALIGN trial (N=252) was terminated early after apixaban-treated patients with mechanical heart valves showed higher rates of thromboembolic events and bleeding compared with warfarin. [11] The FDA subsequently issued a contraindication for all DOACs in mechanical valve patients. BCBSIL denials for this indication are medically appropriate and will not succeed on appeal.

Antiphospholipid Syndrome (Triple Positive)

The TRAPS trial (N=120) showed rivaroxaban was inferior to warfarin in triple-positive antiphospholipid syndrome, with a 12% event rate versus 0% in the warfarin arm (P=0.004). [12] By extension, BCBSIL and most payers decline DOAC coverage for this specific subgroup. Warfarin with strict INR monitoring remains the standard of care per European Society of Cardiology guidelines.

Doses Outside FDA Labeling

Requests for Eliquis at doses other than 2.5 mg or 5 mg twice daily (the two approved strengths) are routinely denied as non-FDA-approved use. The 10 mg twice daily dose used during the first seven days of DVT/PE treatment is covered because it is within the FDA label. [1]

Documentation Checklist for Prescribers

Submitting a complete PA request on the first attempt cuts the authorization timeline significantly. The following checklist reflects the most common documentation gaps identified by BCBSIL's pharmacy benefit manager.

• Confirmed ICD-10 diagnosis code matching an FDA-approved indication
• Most recent CrCl calculation (date and method)
• CHA2DS2-VASc score for AFib indications (must be 2+ for men, 3+ for women to meet ACC/AHA threshold) [5]
• HAS-BLED score if relevant to justify DOAC over warfarin
• Documentation of prior warfarin trial outcome OR specific contraindication
• Signed attestation that the patient does not have a mechanical heart valve or moderate-to-severe mitral stenosis
• Office notes from the most recent cardiology or hematology visit
• If appealing: printed summary of ARISTOTLE or AMPLIFY trial findings relevant to the patient's case [2][3]

A complete initial submission reduces average PA processing time at most BCBSIL plans from 10 to 15 business days down to 3 to 5 business days, based on prescriber-reported experience with major Illinois cardiology practices.